RGX-104
Based on 3 publication(s) in Google Scholar
RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
For research use only. We do not sell to patients.
- Purity: 99.76%
- CAS No.: 610318-54-2
- Formula: C34H33ClF3NO3
- Molecular Weight:596.08
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) RGX-104
More
Biological Activity
LXR[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | EC50 |
17 nM
Compound: 14b, SB-742881
|
Induction of [3H]cholesterol efflux in mouse RAW264.7 cells loaded with acetylated-LDL after 24 hrs
Induction of [3H]cholesterol efflux in mouse RAW264.7 cells loaded with acetylated-LDL after 24 hrs
|
[PMID: 19717304] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD SCID or RAG mice injected with 1×106 SKOV3 ovarian cancer cells[1].
-
Dosage:100 mg/kg.
-
Administration:Oral administration daily for about 60 days.
-
Result:Robustly suppressed tumor growth and progression.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 610318-54-2
-
Appearance Solid
-
Molecular Weight 596.08
-
Formula C34H33ClF3NO3
-
Color White to off-white
-
SMILES
O=C(O)CC1=CC=CC(OCC[C@H](N(CC2=CC=CC(C(F)(F)F)=C2Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4)C)=C1
-
Synonyms
Abequolixron
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jan;637(8048):1198-1206. PMID: 39567700 -
Cancer Cell
Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity. [Abstract]2023 Jul 10;41(7):1276-1293.e11. PMID: 37244259 -
J Adv Res
Plasma apolipoprotein E protein attenuates pulmonary fibrosis through LRP1 and PLAU dual receptor-mediated TGF-β/Smad inhibition. [Abstract]2025 Dec 29:S2090-1232(25)01035-5. PMID: 41475664
Solvent & Solubility
DMSO : 100 mg/mL (167.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (3.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.49 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6776 mL | 8.3881 mL | 16.7763 mL | 41.9407 mL |
| 5 mM | 0.3355 mL | 1.6776 mL | 3.3553 mL | 8.3881 mL | |
| 10 mM | 0.1678 mL | 0.8388 mL | 1.6776 mL | 4.1941 mL | |
| 15 mM | 0.1118 mL | 0.5592 mL | 1.1184 mL | 2.7960 mL | |
| 20 mM | 0.0839 mL | 0.4194 mL | 0.8388 mL | 2.0970 mL | |
| 25 mM | 0.0671 mL | 0.3355 mL | 0.6711 mL | 1.6776 mL | |
| 30 mM | 0.0559 mL | 0.2796 mL | 0.5592 mL | 1.3980 mL | |
| 40 mM | 0.0419 mL | 0.2097 mL | 0.4194 mL | 1.0485 mL | |
| 50 mM | 0.0336 mL | 0.1678 mL | 0.3355 mL | 0.8388 mL | |
| 60 mM | 0.0280 mL | 0.1398 mL | 0.2796 mL | 0.6990 mL | |
| 80 mM | 0.0210 mL | 0.1049 mL | 0.2097 mL | 0.5243 mL | |
| 100 mM | 0.0168 mL | 0.0839 mL | 0.1678 mL | 0.4194 mL |